Get the Stockscreener App
61.35
5.10%
-3.30
After Hours:
60.46
-0.89
-1.45%
Verona Pharma Plc Adr stock is traded at $61.35, with a volume of 1.63M.
It is down -5.10% in the last 24 hours and up +4.43% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$64.65
Open:
$64
24h Volume:
1.63M
Relative Volume:
1.27
Market Cap:
$5.21B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
-30.68
EPS:
-2
Net Cash Flow:
$-103.81M
1W Performance:
-7.00%
1M Performance:
+4.43%
6M Performance:
+118.79%
1Y Performance:
+278.00%
1-Day Range:
$59.50
$64.59
1-Week Range:
$59.50
$69.90
52-Week Range:
$11.39
$70.40
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Compare VRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
61.35 | 5.21B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Oct-03-24 | Initiated | Wells Fargo | Overweight |
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Keeping an Eye on Gilead Sciences, Inc (GILD) After Insider Trading Activity - Knox Daily
McEwen Mining Inc (MUX) Becoming More Attractive for Investors - Knox Daily
Morgan Stanley Upgrades Solaredge Technologies Inc (SEDG) to an Equal-weight from an Underweight - Knox Daily
Verona Pharma at Leerink Global Healthcare: Eutuvera’s Promising Launch By Investing.com - Investing.com UK
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts By Investing.com - Investing.com South Africa
Verona Pharma stock surges as Q4 revenue soars past estimates - Investing.com India
Verona Pharma stock surges as Q4 revenue soars past estimates By Investing.com - Investing.com Canada
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts - Investing.com
Verona Pharma plc (NASDAQ:VRNA) Q4 2024 Earnings Call Transcript - MSN
Verona Pharma ADR earnings beat by $0.02, revenue topped estimates - Investing.com UK
A company insider recently sold 640,264 shares of Verona Pharma Plc ADR [VRNA]. Should You Sale? - Knox Daily
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update - GlobeNewswire Inc.
Verona Pharma stock soars to all-time high of $62.09 - Investing.com India
Verona Pharma stock soars to all-time high of $62.09 By Investing.com - Investing.com South Africa
Canaccord raises Verona Pharma target to $72; maintains buy By Investing.com - Investing.com South Africa
Investor’s Delight: Lithium Americas Corp (NewCo) (LAC) Closes Weak at 2.97, Down -1.98 - The Dwinnex
There is no doubt that Verona Pharma Plc ADR (VRNA) ticks all the boxes. - SETE News
Analyzing Verona Pharma Plc ADR (VRNA) After Recent Trading Activity - Knox Daily
Rumble Inc (RUM)’s Market Momentum: Closing Strong at 12.25, Down -3.92 - The Dwinnex
Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.66, Up/Down -2.12 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: OrganiGram Holdings Inc (OGI) - SETE News
Are Smart Investors Making the Right Decision? Verona Pharma Plc ADR (VRNA) - SETE News
Healthy Upside Potential: Solidion Technology Inc (STI) - SETE News
Stock Surge: XPO Inc (XPO) Closes at 131.50, Marking a 2.24 Increase/Decrease - The Dwinnex
Closing Figures Unveiled: Diageo plc ADR (DEO) Drop -0.84, Closes at 115.95 - The Dwinnex
Market Watch Highlights: Verona Pharma Plc ADR (VRNA) Ends on an Upturn Note at 59.94 - The Dwinnex
Market Momentum Report: Lemonade Inc (LMND)’s Positive Close at 33.99 - The Dwinnex
Stock Market News and Commentary - Barchart
Verona Pharma Keeps Hitting New Highs - Barchart
An Analysis of Knowles Corp (KN)’s Potential Price Growth - Knox Daily
Checking in on Verona Pharma Plc ADR (VRNA) after recent insiders movement - Knox Daily
A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News
Have you been able to find a good deal on Verona Pharma Plc ADR’s shares? - US Post News
The Agilon Health Inc (AGL) had a good session last reading, didn’t it? - US Post News
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Verona Pharma stock target upgraded, retains buy on Q4 results By Investing.com - Investing.com South Africa
Looking For A Top Momentum Pick? Why Valley National Bancorp (NASDAQ: VLY) Is A Great Choice - Stocks Register
Hertz Global Holdings Inc (NASDAQ: HTZ): Overvalued Compared To Others? - Stocks Register
Verona Pharma Plc ADR (VRNA) Outlook: Looking Back For Insights - Stocks Register
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week - Yahoo! Voices
Verona Pharma stock target increased, keeps buy on Q4 sales By Investing.com - Investing.com South Africa
Verona Pharma stock soars to all-time high of $49.05 - Investing.com India
Here are some of BTIG's top picks for the first half of 2025 - Investing.com
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Verona Pharma stock soars to all-time high of $43.76 - Investing.com
Ligand forecasts revenue growth and higher earnings for 2025 - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):